Tag: drug delivery

Food for Thought: Weekly Wrap-Up

The human genome of newborns contains an unexpectedly low number of mutations, writes Joachim Müller-Jung in Frankfurter Allgemeine Zeitung (FAZ). Contrary to earlier estimates of 100-200 mutations generated in the germ cells of parents, the number is only about 60. Results come from sequencing the entire genomes of two families with one child each. The results have implications for understanding human evolution and genetics.

Sonja Kastilian, also in FAZ, features a preliminary report of IQWiG, Germany’s watchdog agency appraising drugs and treatments for quality and cost effectiveness, on the benefits of HPV testing of women as a screening for ovarian cancer. IQWiG set out to compare DNA tests for HPV with common pap smear tests and reported that the HPV tests leas to an earlier diagnosis and better follow-up examinations, regardlesss of whether it is applied alone or in combination with the conventional test. A final decision on whether the test is to be reimbursed by Germany’s statutory healthcare system is expected for 2012. In 2006, the Joint Federal Committee (G-BA), the body in charge, had voted against reimbursement for cost reasons. Kastilian also points out that HPV vaccination rates at present are below 30% in young women in Germany, in contrast to up to 81% in the UK, Portugal, and Australia. Reason has been an unduly discussion in German media about potential risks, high costs and lack of efficacy.

Uta Neubauer in Neue Zürcher Zeitung (NZZ) reports on novel approaches to use cold plasma to disinfect wounds, hands, and food. A method and device developed by the German Max Planck Institute for Extraterrestrial Physics has already demonstrated safety and efficacy in treating wounds and disinfecting hands. At present, it is under investigation for the treatment of foods, e.g. food additives and berries.

Sven Titz, also in NZZ, deals with latest insights into the physics of the water surface. Using vibration spectroscopy, physicists of the University of Southern California at Los Angeles found that the surface is made up basically by -OH groups of the water molecules sticking out from the liquid. The discovery will lead to better understanding solubility of molecules in water.

Forbes this week introduces two innovations in optics. Jennifer Hicks writes about the “socialization of the microscope” by a technology that allows the display of microscopic images on an extremely large multitouch screen, just like an oversized iPad. Thereby, groups of students, pathologists or researchers can focus on tiny details by touching, gesturing, and zooming in and out. A video of the microscope at work can be found here.

Californian-based start-up Lytro has unveiled a camera that can take pictures without focusing, writes Tomio Geron in Forbes. Instead, focusing on any point of interest in the photo is done once the image is loaded on a computer. The consumer camera is based on the light field technology invented by Stanford University researchers. The camera is fitted with special lenses and a sensor that captures every ray of light hitting it, regardless of whether it is from the fore- or the background, and records its individual color, intensity and direction. The camera therefore also can be used to generate 3D-pictures. Examples can be found here.

The Economist this week introduces an intelligent drug delivery approach using nanoparticles. It can be used to deliver anti-cancer chemotherapeutic drugs and makes use of the blood-clotting mechanism: first, nano-sized golden rods are injected into the blood stream. They fit into the unusual pores common in capillaries nourishing tumors and thereby mark tumor sites. Once they are in place, the tumor site is treated with laser light bursts. Their energy is absorbed by the gold and converted to heat destroying the capillaries so that the body’s coagulation system is triggered to repair the damage. This is when the second nanoparticles come into play. They carry the chemotherapeutics together with a fibrin-binding protein fragment and are designed to release the drug upon fibrin-binding only. The treatment strategy therefore delivers the drug exactly to the site the coagulation system is active, that is, at the tumor. The method developed at the Massachusetts Institute of Technology (MIT) has proven safety and efficacy in mice and will be tested in humans soon.

Researchers from the University of Rochester have come up with just another idea to release drugs on target, the New Scientist reports. They found that nanocarbon tubes containing aqueous solutions can be made to pop open by heating them from the outside with infrared lasers. Patients could be administered nanocontainers carrying drugs to deliver it to a desired target where the drug then is released by laser light.

And finally, Die Welt this week deals with wrinkles and high tech attempts to avoid or get rid of them. Clinical studies in people with an average age of 87 prove that vitamin A1 (retinol) is useful to smooth skin. Also, light from LEDs is able to remove a water film caging the skin’s elastic fibers so that they become rigid. The method is best applied by pre-treating the skin with green tee polyphenols to deactivate free radicals generated by the LEDs. Moreover, scientists from Hamburg-based Skin Investigation and Technology SIT found out that eating one bar of dark chocolate a day also leads to a 34% improvement of skin elasticity after 6 months. Further attempts to eliminate wrinkles are being made by using signaling peptides activating collagen-producing cells and by polymers carrying nanoparticles that are injected between outer and inner skin layers. The resulting films disperse the compression forces within the skin, thereby “ironing” it from inside.

Company News: SoluBest – A Solution Solution

– Drug Delivery Partnership with Dr. Reddy´s Announced Today –

Investors and media alike use to think of drug delivery as a boring aspect of today’s biotech and pharma business. However, noting that 40% of marketed drugs have solubility issues that cannot be easily solved and about 70% of compounds in discovery are so insoluble that they do not have adequate and consistent gastrointestinal absorption to ensure efficacy, it is clear that the problem is not trivial.

One can look at the problem also from another angle: take, for example, diclofenac, a widely used drug for the treatment of pain and inflammation. In Germany alone, patients consume about 90 metric tons per year. As about 70% of the drug is excreted unchanged because of poor solubility, this means that each year 63 tons are released into sanitary wastewater and ultimately into the environment, as sewage plants cannot clear it from the water. It is long since known that Diclofenac causes damage to fish gills and kidneys.

Better solubility of drugs means improved bioavailability and less substance necessary for the desired therapeutic effect.

There are numerous physical and chemical approaches to improve solubility, including particle size reduction, drug dispersion, complexation and microemulsions as well as nanotechnology approaches – however most add considerable costs and complexity to manufacturing and do not create novel IP.

Enter SoluBest, a new client of akampion: the company is using self-assembling constructs in which active drug molecules are uniquely interwoven with FDA-approved polymers. Once in the body, these oral, solid-dosage formulations disintegrate into colloidal dispersions, increasing drug solubility and absorption, thus improving the bio-performance of insoluble drugs and nutritional actives. Today, the company disclosed the signing of a drug delivery collaboration with Dr. Reddy’s to develop new, proprietary formulations for the Indian drug giant (see press release).

The main advantages of SoluBest’s technology are two-fold. For one, thanks to the self-assembling property of the polymers, the procedure involves just 2 steps: the preparation of a liquid feed, followed by its spray drying to obtain a solid, oral formulation. As a result, the procedure does not add extra complexity to the manufacturing process. Moreover, each formulation can be protected by composition of matter patents and therefore is ideally suited for life-cycle management.
Once in the body, formulation disintegrates into colloidal dispersions, increasing drug solubility and absorption, thus improving the bio-performance of insoluble drugs and nutritional actives.